MitoRx's lead drug Myo-004 targets mitochondrial dysfunction through persulfide signaling rather than appetite suppression, addressing what they claim is a root cause of metabolic disease.
Unlike GLP-1 drugs that can cause up to 40% muscle mass loss, MitoRx's preclinical data shows not just muscle preservation but actual increases in muscle mass alongside comparable fat loss.
While GLP-1s show impressive clinical trial results (10-15% weight loss), real-world data reveals much more modest outcomes - just 4.7% weight loss in a two-year follow-up study, creating market opportunity for alternatives.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

More from Innovation